心臓組織工学市場 – 2029年までの世界予測

Report Overview

The global cardiac tissue engineering market is projected to reach USD 1,333.6 Million by 2029 from USD 621.2 Million in 2024, at a CAGR of 16.5% from 2024 to 2029.

世界の心臓組織工学市場は、2024年から2029年までCAGR 16.5%で、2024年の6億2,120万米ドルから2029年までに13億3,360万米ドルに達すると予測されています。

The growth of the market is driven Technological advancement in 3d bioprinting. The market also benefits from the up surge in prevalence of cardiovascular diseases across the globe. However, high cost associated with treating cardiovascular diseases by cardiac tissue engineering process, is impacting the growth of the market. Moreover, the stringent regulatory policies in the field of cardiac tissue engineering are a major factor restraining the market growth.

“Hydrogel based scaffolds segment to witness the significant growth during the forecast period.”

Based on material, the segment is divided into stem cells, and scaffolds. The scaffolds segment is further divided into synthetic scaffolds and biological scaffolds. The biological scaffolds are further segmented into collagen-based scaffolds and hydrogel-based scaffolds. In 2023, among these two biological scaffolds, the hydrogel-based scaffolds accounts for the significant share in cardiac tissue engineering market. This is due to their versatile properties that closely mimic natural tissue characteristics. Hydrogels are composed of highly hydrated networks, like the extracellular matrix, which promotes cell attachment, proliferation, and differentiation critical for tissue regeneration. Their mechanical properties can be tailored across a wide range to match those of specific tissues, enhancing compatibility and integration within the body. This tunability allows for the design of scaffolds with optimal porosity, biodegradability, and permeability, facilitating nutrient and oxygen diffusion essential for cell survival and tissue development. Moreover, hydrogels can be engineered to deliver bioactive molecules and growth factors in a controlled manner, further supporting tissue regeneration processes. Compared to collagen-based scaffolds, which also offer biological compatibility but have more limited mechanical tunability, hydrogels provide a superior platform for creating complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications. These advantages position hydrogel-based scaffolds as the preferred choice, driving their dominance in the biological scaffold segment of the scaffold market.

The segment is separated into scaffolds and stem cells based on the type of material. The material used on scaffolds is subdivided into two categories: biological scaffolds and synthetic scaffolds. Collagen- and hydrogel-based scaffolds are two further categories into which the biological scaffolds are divided. By 2023, the hydrogel-based biological scaffolds will have a larger market share in cardiac tissue engineering than the other two biological scaffolds combined. This is because of its adaptable qualities, which closely resemble those of natural tissue. Similar to the extracellular matrix, hydrogels are made of highly hydrated networks that support cell adhesion, proliferation, and differentiation—all of which are essential for tissue regeneration. Their ability to modify their mechanical characteristics to a large degree in order to match the characteristics of particular tissues improves their compatibility and integration with the body. dominance in the scaffold market’s biological scaffold sector. Because of its tunability, scaffolds with the ideal porosity, biodegradability, and permeability may be designed, enabling the flow of nutrients and oxygen—both of which are necessary for tissue formation and cell survival. Hydrogels can also be designed to supply growth factors and bioactive compounds in a regulated way, which will aid in the processes involved in tissue regeneration. For the creation of complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications, hydrogels offer a superior platform than collagen-based scaffolds, which likewise offer biological compatibility but have less mechanical tunability. Because of these benefits, hydrogel-based scaffolds are positioned as the best option and dominate the market for biological scaffolds.

“Congenital heart disease treatment segment accounted for the significant share in the cardiac tissue engineering market during the forecast period.”

Based on application, the cardiac tissue engineering market is segmented into myocardial infarction, heart valve repair/replacement, congenital heart disease treatment and others. Among these in 2023, the congenital heart disease treatment accounted for significant share. This is attributed to the rising prevalence and critical medical needs associated with congenital heart defects globally. For instance, in Australia, approximately 65,000 individuals live with congenital heart disease, with around 5,900 cases diagnosed annually as the principal cause. This condition also accounts for 79 infant deaths annually, highlighting its severe impact on public health. Similarly, in the United States, nearly 40,000 infants are born with congenital heart defects each year, underscoring the substantial patient population requiring advanced treatment options. Cardiac tissue engineering offers promising solutions for congenital heart defects by providing tailored approaches to repair or replace defective heart tissues. These innovations are crucial in addressing the specific anatomical and physiological challenges presented by congenital heart diseases, which often require personalized and durable interventions from early infancy throughout adulthood. The increasing incidence of congenital heart defects globally drives demand for innovative therapies that can improve patient outcomes and quality of life, thereby bolstering the congenital heart disease segment’s prominence in the cardiac tissue engineering market.

The cardiac tissue engineering market is divided into segments based on application, comprising treatment for congenital heart disease, myocardial infarction, and heart valve repair/replacement. Treatment for congenital cardiac disease accounted for a sizable portion of these in 2023. This is explained by the increased global prevalence of congenital cardiac abnormalities and the urgent medical needs they provide. For example, congenital heart disease affects about 65,000 people in Australia, with 5,900 new instances being diagnosed as the primary cause each year. Its devastating influence on public health is further evidenced by the 79 newborn fatalities that are attributed to this illness each year. Comparably, over 40,000 babies in the US are born with congenital cardiac abnormalities every year, highlighting the sizeable patient population in need of cutting-edge care. Cardiac tissue engineering provides customized methods for replacing or repairing damaged cardiac tissues, which presents promising remedies for congenital heart abnormalities. These advancements are essential for tackling the unique anatomical and physiological problems associated with congenital cardiac disorders, which frequently call for customized and long-lasting therapies from early childhood into adulthood. The need for novel treatments that can enhance patient outcomes and quality of life is being driven by the rising incidence of congenital heart problems worldwide. This is expected to increase the importance of the congenital heart disease segment in the cardiac tissue engineering market.

“APAC is estimated to register the highest CAGR during the forecast period.”

In this report, the cardiac tissue engineering market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period attributed to increase in strategic collaborations and robust research initiatives. In June 2023, the establishment of the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), involving patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank, underscored a concerted effort across nine health systems in Asia to enhance heart health and mitigate cardiovascular disease (CVD) impacts. Moreover, the presence of esteemed research institutions such as the Heart Research Institute, dedicated to advancing cardiovascular disease pathophysiology and pioneering tissue engineering solutions, enhances the region’s capability to innovate in cardiac health technologies. With such collaborative frameworks and research capabilities, the Asia Pacific region is accelerating in scientific advancements for market growth in cardiac tissue engineering, promising significant opportunities for stakeholders in the sector.

.

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five main geographical regions into which the cardiac tissue engineering market is divided in the report. Due to a rise in strategic partnerships and active research projects, the APAC market is anticipated to grow at the fastest rate over the forecast period. The Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was founded in June 2023 and represents a coordinated effort across nine Asian health systems to improve heart health and lessen the effects of cardiovascular disease (CVD). Participants in the alliance include patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank. Furthermore, the region’s capacity to innovate in heart health technologies is further enhanced by the existence of prestigious research organizations like the Heart Research Institute, which is committed to studying the pathophysiology of cardiovascular illness and developing innovative tissue engineering treatments. The Asia Pacific area is experiencing a notable surge in scientific developments for cardiac tissue engineering market growth, thanks to the presence of collaborative frameworks and research capacities. This presents substantial prospects for industry stakeholders.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW (16%)

List of Companies Profiled in the Report

o            Terumo corporation (Japan)

o            Artivion, Inc. (US)

o            Baxter international, Inc. (US)

o            Teijin Limited (Japan)

o            Medtronic Plc. (Ireland)

o            Boston Scientific Corporation (US)

o            Abbott Laboratories (US)

o            Merck KGaA (Germany)

o            Elutia. (US)

o            W. L. Gore & Associates, Inc. (US)

o            Meril Lifesciences Pvt.Ltd (India)

o            Fujifilm Holdings Corporation (Japan)

o            Vascudyne, Inc. (US)

o            BICO – THE BIO CONVERGENCE COMPANY (Sweden)

o            ReproCELL, Inc. (US)

o            PromoCell GmBH (Germany)

o            Axol Bioscience Ltd. (UK)

o            BPS Bioscience, Inc. (US)

o            Cell Application, Inc. (US)

o            Viscofan DE GmBH (Germany)

Research Coverage

This report studies the cardiac tissue engineering market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total cardiac tissue engineering market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (rising prevalence of cardiovascular diseases, increase in support from major market players and government bodies, Increased demand for regenerative medicine, the advancement of 3D bioprinting),restraints (High cost of treatment, Complex regulatory process), challenges (Safety concerns and complexity of biomaterials, Limited awareness and scarcity of skilled professionals), opportunities (Technological advancement in cardiac tissue engineering, The ability of biomaterials to enhance the functionality and integration of cardiac tissues offers significant opportunities, Increase in research of stems cells to treat cardiovascular diseases) contributing the growth of the cardiac tissue engineering market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the cardiac tissue engineering market.
• Market Development: Comprehensive information on the lucrative emerging markets, product, procedure, technology, application, end-user and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the cardiac tissue engineering market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global cardiac tissue engineering market.

Table of Contents

1            INTRODUCTION            31

1.1         STUDY OBJECTIVES      31

1.2         MARKET DEFINITION   31

1.2.1      MATERIAL DEFINITION             32

1.2.2      PRODUCT DEFINITION 32

1.2.3      APPLICATION DEFINITION       33

1.2.4      END USER DEFINITION 33

1.2.5      INCLUSIONS & EXCLUSIONS     34

1.3         MARKET SCOPE             35

1.3.1      MARKETS COVERED     35

1.3.2      YEARS CONSIDERED     36

1.3.3      CURRENCY CONSIDERED          36

1.4         STAKEHOLDERS            36

1.5         LIMITATIONS   37

2            RESEARCH METHODOLOGY     38

2.1         RESEARCH APPROACH 38

2.2         RESEARCH METHODOLOGY DESIGN    38

2.2.1      SECONDARY RESEARCH             39

2.2.2      KEY DATA FROM SECONDARY SOURCES            40

2.2.3      PRIMARY DATA 41

2.2.4      KEY DATA FROM PRIMARY SOURCES    42

2.2.5      KEY INDUSTRY INSIGHTS          42

2.3         MARKET SIZE ESTIMATION       43

2.4         MARKET BREAKDOWN & DATA TRIANGULATION          48

2.5         MARKET SHARE ESTIMATION   49

2.6         STUDY ASSUMPTIONS  49

2.7         RISK ASSESSMENT         49

2.8         RESEARCH LIMITATIONS           50

2.8.1      METHODOLOGY-RELATED LIMITATIONS         50

3            EXECUTIVE SUMMARY 51

4            PREMIUM INSIGHTS      57

4.1         CARDIAC TISSUE ENGINEERING MARKET OVERVIEW   57

4.2         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION              58

4.3         REGIONAL SNAPSHOT OF CARDIAC TISSUE ENGINEERING MARKET (2023)   59

4.4         GEOGRAPHIC MIX: CARDIAC TISSUE ENGINEERING MARKET,

2024–2029 (USD MILLION)          60

4.5         CARDIAC TISSUE ENGINEERING MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)    60

5            MARKET OVERVIEW     61

5.1         INTRODUCTION            61

5.2         MARKET DYNAMICS     61

5.2.1      DRIVERS            62

5.2.1.1   Rising prevalence of cardiovascular diseases  62

5.2.1.2   Increase in support from major market players and government bodies    63

5.2.1.3   Increased demand for regenerative medicine 63

5.2.1.4   Advancements in 3D bioprinting     64

5.2.2      RESTRAINTS     64

5.2.2.1   High cost of treatment       64

5.2.2.2   Complex regulatory process             65

5.2.3      OPPORTUNITIES           65

5.2.3.1   Technological advancements in cardiac tissue engineering         65

5.2.3.2   Enhanced functionality and integration of cardiac tissues using biomaterials              66

5.2.3.3   Increase in stem cell research to treat cardiovascular diseases    66

5.2.4      CHALLENGES   67

5.2.4.1   Safety concerns and complexity of biomaterials            67

5.2.4.2   Limited awareness and availability of skilled professionals         67

5.3         INDUSTRY TRENDS       68

5.3.1      DEVELOPMENT OF BIOCOMPATIBLE AND BIODEGRADABLE MATERIALS      68

5.3.2      INTEGRATION OF MICROFLUIDICS AND ELECTRICAL STIMULATION FOR IMPROVED CELL FUNCTION AND TISSUE MATURATION   69

5.3.3      EXPANSION OF CARDIAC TISSUE ENGINEERING APPLICATIONS              69

5.4         TECHNOLOGY ANALYSIS           69

5.4.1      KEY TECHNOLOGIES    69

5.4.2      STEM CELL TECHNOLOGY        69

5.4.3      3D BIOPRINTING           70

5.4.4      BIOREACTORS 70

5.4.5      COMPLEMENTARY TECHNOLOGY        71

5.4.6      GENE EDITING 71

5.4.7      ELECTROSPINNING      71

5.4.8      MICROFLUIDICS            72

5.4.9      ADJACENT TECHNOLOGIES      72

5.4.9.1   Biosensors           72

5.4.10    ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING 73

5.4.11    NANOTECHNOLOGY    73

5.5         PIPELINE ANALYSIS      74

5.6         VALUE CHAIN ANALYSIS            75

5.7         PORTER’S FIVE FORCES ANALYSIS         76

5.7.1      THREAT OF NEW ENTRANTS    76

5.7.2      THREAT OF SUBSTITUTES         76

5.7.3      BARGAINING POWER OF SUPPLIERS     76

5.7.4      BARGAINING POWER OF BUYERS           77

5.7.5      INTENSITY OF COMPETITIVE RIVALRY 77

5.8         KEY STAKEHOLDERS AND BUYING CRITERIA    77

5.8.1      KEY STAKEHOLDERS IN BUYING PROCESS         77

5.8.2      BUYING CRITERIA         78

5.9         REGULATORY LANDSCAPE       79

5.9.1      REGULATORY ANALYSIS            79

5.9.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          79

5.10       PATENT ANALYSIS        81

5.10.1    PATENT PUBLICATION TRENDS FOR CARDIAC TISSUE ENGINEERING MARKET            82

5.10.2    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS        82

5.11       TRADE ANALYSIS          85

5.11.1    TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS              86

5.11.2    IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2021 (USD MILLION)    86

5.11.3    EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2021 (USD MILLION)    86

5.12       PRICING ANALYSIS        86

5.13       KEY CONFERENCES AND EVENTS, 2024–2025     87

5.14       UNMET NEEDS IN CARDIAC TISSUE ENGINEERING MARKET     88

5.15       END USER EXPECTATIONS IN CARDIAC TISSUE ENGINEERING MARKET            89

5.16       AI INTEGRATION IN CARDIAC TISSUE ENGINEERING MARKET 89

5.17       ECOSYSTEM ANALYSIS 90

5.18       CASE STUDIES  92

5.19       SUPPLY CHAIN ANALYSIS          94

5.20       CARDIAC TISSUE ENGINEERING MARKET: INVESTMENT AND FUNDING SCENARIO     96

5.21       ADJACENT MARKET ANALYSIS 96

5.21.1    TISSUE ENGINEERING MARKET 96

6            CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL           98

6.1         INTRODUCTION            99

6.2         STEM CELLS     99

6.2.1      INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET              99

6.3         SCAFFOLDS      102

6.3.1      SYNTHETIC SCAFFOLDS            105

6.3.1.1   Advancements in fabrication techniques to drive market            105

6.3.2      BIOLOGICAL SCAFFOLDS          107

6.3.3      COLLAGEN-BASED SCAFFOLDS 110

6.3.3.1   Biocompatibility of material – key driver        110

6.3.3.2   Hydrogel-based scaffolds   112

6.3.3.2.1 Low mechanical strength to restrain segment growth   112

7            CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT            115

7.1         INTRODUCTION            116

7.2         VASCULAR GRAFTS       117

7.2.1      INCREASE IN PREVALENCE OF CORONARY ARTERY DISEASE TO DRIVE MARKET            117

7.3         CARDIAC PATCHES       119

7.3.1      INCREASE IN CLINICAL TRIALS FOR CARDIAC PATCHES TO BOOST MARKET            119

7.4         HEART VALVES 121

7.4.1      INCREASE IN PREVALENCE OF VALVE REGURGITATION TO DRIVE MARKET            121

8            CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION     124

8.1         INTRODUCTION            125

8.2         MYOCARDIAL INFARCTION      126

8.2.1      IMPROVED STRUCTURAL INTEGRATION TO DRIVE MARKET GROWTH              126

8.3         HEART VALVE REPAIR/REPLACEMENT 128

8.3.1      INCREASE IN INCIDENCE OF AORTIC STENOSIS TO DRIVE MARKET              128

8.4         CONGENITAL HEART DISEASE 130

8.4.1      SIGNIFICANT INVESTMENT BY KEY MARKET PLAYERS TO DRIVE MARKET            130

8.5         OTHER APPLICATIONS 132

9            CARDIAC TISSUE ENGINEERING MARKET, BY END USER             135

9.1         INTRODUCTION            136

9.2         HOSPITALS & CLINICS  137

9.2.1      ADVANCED INFRASTRUCTURE AND ACCESS TO CLINICAL TRIALS – KEY DRIVERS    137

9.3         ACADEMIC & RESEARCH INSTITUTES   139

9.3.1      AVAILABILITY OF FUNDING FOR RESEARCH – KEY DRIVER        139

9.4         OTHER END USERS        141

10          CARDIAC TISSUE ENGINEERING MARKET, BY REGION  144

10.1       INTRODUCTION            145

10.2       NORTH AMERICA          146

10.2.1    MACROECONOMIC OUTLOOK FOR NORTH AMERICA   147

10.2.2    US         152

10.2.2.1 Increasing government grants for research to drive market        152

10.2.3    CANADA            157

10.2.3.1 Availability of funding for research on regenerative medicine to fuel market              157

10.3       EUROPE             162

10.3.1    MACROECONOMIC OUTLOOK FOR EUROPE     162

10.3.2    UK         167

10.3.2.1 Fastest-growing market for cardiac tissue engineering in Europe             167

10.3.3    GERMANY         172

10.3.3.1 Rising prevalence of cardiovascular diseases – key driver            172

10.3.4    FRANCE             177

10.3.4.1 Increasing focus on regenerative medicine to boost market        177

10.3.5    ITALY   182

10.3.5.1 Insufficient research funding to restrain growth of market         182

10.3.6    SPAIN   186

10.3.6.1 Increase in R&D investment to drive market growth    186

10.3.7    REST OF EUROPE           191

10.4       ASIA PACIFIC    196

10.4.1    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC          196

10.4.2    JAPAN  203

10.4.2.1 Increasing aging population to drive market growth     203

10.4.3    CHINA  208

10.4.3.1 Major cardiac tissue engineering market in Asia Pacific             208

10.4.4    INDIA   213

10.4.4.1 Increasing government initiatives for clinical trials in stem cell research to boost market   213

10.4.5    AUSTRALIA       218

10.4.5.1 Growing government support to fuel market  218

10.4.6    SOUTH KOREA 223

10.4.6.1 Advancements in technology and strong government support to drive market growth   223

10.4.7    REST OF ASIA PACIFIC  228

10.5       LATIN AMERICA             233

10.5.1    MACROECONOMIC OUTLOOK FOR LATIN AMERICA     233

10.5.2    BRAZIL 238

10.5.2.1 Increase in prevalence of congenital heart disease to drive market            238

10.5.3    MEXICO             243

10.5.3.1 Rapidly growing geriatric population – key driver         243

10.5.4    REST OF LATIN AMERICA          248

10.6       MIDDLE EAST & AFRICA             252

10.6.1    EXPANDING NETWORK OF ADVANCED HEALTHCARE FACILITIES TO SUPPORT MARKET GROWTH    252

10.6.2    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA     252

10.6.3    GCC COUNTRIES           257

10.6.3.1 Increased inclination toward novel therapies – key driver           257

10.6.4    REST OF MIDDLE EAST & AFRICA           262

11          COMPETITIVE LANDSCAPE       267

11.1       OVERVIEW        267

11.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          267

11.3       REVENUE SHARE ANALYSIS       268

11.4       MARKET SHARE ANALYSIS         269

11.5       VALUATION AND FINANCIAL METRICS OF HEALTHCARE SERVICE VENDORS          272

11.6       COMPANY EVALUATION MATRIX, KEY PLAYERS (2023) 273

11.6.1    STARS  273

11.6.2    EMERGING LEADERS    273

11.6.3    PERVASIVE PLAYERS     273

11.6.4    PARTICIPANTS 273

11.6.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      275

11.6.5.1 Company footprint            275

11.6.5.2 Region footprint  276

11.6.5.3 Application footprint         277

11.6.5.4 Product footprint 278

11.6.5.5 Material footprint 279

11.6.5.6 End user footprint             280

11.7       COMPANY EVALUATION MATRIX, STARTUPS/SMES (2023)        280

11.7.1    PROGRESSIVE COMPANIES       280

11.7.2    RESPONSIVE COMPANIES          281

11.7.3    DYNAMIC COMPANIES 281

11.7.4    STARTING BLOCKS       281

11.7.5    COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES         282

11.7.5.1 Detailed list of key startups/smes     282

11.7.5.2 Competitive benchmarking of key startups/SMEs        282

11.8       COMPETITIVE SCENARIO          283

11.8.1    PRODUCT LAUNCHES  283

11.8.2    DEALS  284

11.9       BRAND/PRODUCT COMPARATIVE ANALYSIS    286

12          COMPANY PROFILES    287

12.1       KEY PLAYERS   287

12.1.1    TERUMO CORPORATION           287

12.1.1.1 Business overview 287

12.1.1.2 Products offered  288

12.1.1.3 MnM view           289

12.1.1.3.1            Right to win         289

12.1.1.3.2            Strategic choices  289

12.1.1.3.3            Weaknesses & competitive threats   289

12.1.2    ARTIVION, INC. 290

12.1.2.1 Business overview 290

12.1.2.2 Products offered  291

12.1.2.3 Recent developments         292

12.1.2.4 MnM view           292

12.1.2.4.1            Right to win         292

12.1.2.4.2            Strategic choices  292

12.1.2.4.3            Weaknesses & competitive threats   293

12.1.3    BAXTER INTERNATIONAL, INC. 294

12.1.3.1 Business overview 294

12.1.3.2 Products offered  295

12.1.3.3 Recent developments         296

12.1.3.4 MnM view           296

12.1.3.4.1            Right to win         296

12.1.3.4.2            Strategic choices  296

12.1.3.4.3            Weaknesses & competitive threats   296

12.1.4    TEIJIN LIMITED             297

12.1.4.1 Business overview 297

12.1.4.2 Products offered  298

12.1.4.3 MnM view           299

12.1.4.3.1            Right to win         299

12.1.4.3.2            Strategic choices  299

12.1.4.3.3            Weaknesses & competitive threats   299

12.1.5    MEDTRONIC PLC           300

12.1.5.1 Business overview 300

12.1.5.2 Products offered  301

12.1.5.3 Recent developments         302

12.1.5.4 MnM view           302

12.1.5.4.1            Right to win         302

12.1.5.4.2            Strategic choices  302

12.1.5.4.3            Weaknesses & competitive threats   303

12.1.6    BOSTON SCIENTIFIC CORPORATION    304

12.1.6.1 Business overview 304

12.1.6.2 Products offered  305

12.1.7    ABBOTT LABORATORIES           306

12.1.7.1 Business overview 306

12.1.7.2 Products offered  307

12.1.7.3 Recent developments         308

12.1.8    MERCK KGAA   309

12.1.8.1 Business overview 309

12.1.8.2 Products offered  310

12.1.9    FUJIFILM HOLDINGS CORPORATION    311

12.1.9.1 Business overview 311

12.1.9.2 Products offered  312

12.1.10  BICO – THE BIO CONVERGENCE COMPANY       313

12.1.10.1             Business overview 313

12.1.10.2             Products offered  314

12.1.11  ELUTIA 315

12.1.11.1             Business overview 315

12.1.11.2             Products offered  316

12.1.12  W. L. GORE AND ASSOCIATES, INC.        317

12.1.12.1             Business overview 317

12.1.12.2             Products offered  317

12.1.13  MERIL LIFESCIENCES PVT. LTD.             318

12.1.13.1             Business overview 318

12.1.13.2             Products offered  318

12.1.14  VASCUDYNE, INC.          319

12.1.14.1             Business overview 319

12.1.14.2             Products offered  319

12.1.15  REPROCELL, INC.           321

12.1.15.1             Business overview 321

12.1.15.2             Products offered  321

12.1.15.3             Recent developments         322

12.2       OTHER PLAYERS           323

12.2.1    AXOL BIOSCIENCE LTD.             323

12.2.2    BPS BIOSCIENCE, INC.   324

12.2.3    TAKARA BIO, INC.          325

12.2.4    XELTIS 325

12.2.5    VISCOFAN DE GMBH     326

12.2.6    CELL APPLICATION, INC            326

12.2.7    PROMOCELL GMBH      327

13          APPENDIX         328

13.1       DISCUSSION GUIDE      328

13.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             333

13.3       CUSTOMIZATION OPTIONS      335

13.4       RELATED REPORTS       335

13.5       AUTHOR DETAILS         336

LIST OF TABLES

TABLE 1             CURRENCY CONVERSION RATES            36

TABLE 2             US: LEADING CAUSES OF DEATHS, 2021–2022    62

TABLE 3             CARDIAC TISSUE ENGINEERING MARKET: R&D PIPELINE              74

TABLE 4             CARDIAC TISSUE ENGINEERING MARKET: PORTER’S FIVE FORCES ANALYSIS         76

TABLE 5             INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF

CARDIAC TISSUE ENGINEERING PRODUCTS     78

TABLE 6             KEY BUYING CRITERIA FOR CARDIAC TISSUE ENGINEERING PRODUCTS       78

TABLE 7             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 79

TABLE 8             EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 80

TABLE 9             ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 80

TABLE 10           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 81

TABLE 11           MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 81

TABLE 12           CARDIAC TISSUE ENGINEERING MARKET: LIST OF PATENTS, 2014–2024          84

TABLE 13           AVERAGE SELLING PRICE OF CARDIAC TISSUE ENGINEERING PRODUCTS (USD)          87

TABLE 14           AVERAGE SELLING PRICE OF KEY CARDIAC TISSUE ENGINEERING PRODUCTS,

BY REGION, 2023 (USD) 87

TABLE 15           CARDIAC TISSUE ENGINEERING MARKET: KEY CONFERENCES

AND EVENTS, 2024–2025             87

TABLE 16           CARDIAC TISSUE ENGINEERING MARKET: UNMET NEEDS              88

TABLE 17           CARDIAC TISSUE ENGINEERING MARKET: END USER EXPECTATIONS             89

TABLE 18           CARDIAC TISSUE ENGINEERING MARKET: AI INTEGRATION              89

TABLE 19           CARDIAC TISSUE ENGINEERING MARKET: ECOSYSTEM ANALYSIS          91

TABLE 20           CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 1              92

TABLE 21           CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 2              93

TABLE 22           CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 3              94

TABLE 23           CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          99

TABLE 24           CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          99

TABLE 25           KEY PROVIDERS OF STEM CELLS           100

TABLE 26           STEM CELLS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          101

TABLE 27           STEM CELLS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          102

TABLE 28           KEY PROVIDERS OF SCAFFOLDS            103

TABLE 29           SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY TYPE,

2021–2023 (USD MILLION)          103

TABLE 30           SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY TYPE,

2024–2029 (USD MILLION)          104

TABLE 31           SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2021–2023 (USD MILLION) 104

TABLE 32           SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2024–2029 (USD MILLION) 105

TABLE 33           SYNTHETIC SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          106

TABLE 34           SYNTHETIC SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          107

TABLE 35           BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY TYPE, 2021–2023 (USD MILLION)       108

TABLE 36           BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY TYPE, 2024–2029 (USD MILLION)       108

TABLE 37           BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          109

TABLE 38           BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          110

TABLE 39           COLLAGEN-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          111

TABLE 40           COLLAGEN-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          112

TABLE 41           HYDROGEL-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          113

TABLE 42           HYDROGEL-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          114

TABLE 43           CARDIAC TISSUE ENGINEERING MARKET, PIPELINE ANALYSIS              116

TABLE 44           CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          116

TABLE 45           CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          117

TABLE 46           VASCULAR GRAFTS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          118

TABLE 47           VASCULAR GRAFTS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          119

TABLE 48           CARDIAC PATCHES: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          120

TABLE 49           CARDIAC PATCHES: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          121

TABLE 50           HEART VALVES: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)        122

TABLE 51           HEART VALVES: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          123

TABLE 52           CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          125

TABLE 53           CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          125

TABLE 54           MYOCARDIAL INFARCTION: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)        127

TABLE 55           MYOCARDIAL INFARCTION: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          128

TABLE 56           HEART VALVE REPAIR/REPLACEMENT: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2021–2023 (USD MILLION)              129

TABLE 57           HEART VALVE REPAIR/REPLACEMENT: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2024–2029 (USD MILLION)              130

TABLE 58           CONGENITAL HEART DISEASE: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          131

TABLE 59           CONGENITAL HEART DISEASE: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          132

TABLE 60           OTHER APPLICATIONS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2021–2023 (USD MILLION)          133

TABLE 61           OTHER APPLICATIONS: CARDIAC TISSUE ENGINEERING MARKET,

BY COUNTRY/REGION, 2024–2029 (USD MILLION)          134

TABLE 62           CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)E        136

TABLE 63           CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          136

TABLE 64           HOSPITALS & CLINICS: CARDIAC TISSUE ENGINEERING MARKET,

BY REGION, 2021–2023 (USD MILLION) 138

TABLE 65           HOSPITALS & CLINICS: CARDIAC TISSUE ENGINEERING MARKET,

BY REGION, 2024–2029 (USD MILLION)  139

TABLE 66           ACADEMIC & RESEARCH INSTITUTES: CARDIAC TISSUE ENGINEERING MARKET,

BY REGION, 2021–2023 (USD MILLION) 140

TABLE 67           ACADEMIC & RESEARCH INSTITUTES: CARDIAC TISSUE ENGINEERING MARKET,

BY REGION, 2024–2029 (USD MILLION) 141

TABLE 68           OTHER END USERS: CARDIAC TISSUE ENGINEERING MARKET, BY REGION,

2021–2023 (USD MILLION)          142

TABLE 69           OTHER END USERS: CARDIAC TISSUE ENGINEERING MARKET, BY REGION,

2024–2029 (USD MILLION)          143

TABLE 70           CARDIAC TISSUE ENGINEERING MARKET, BY REGION, 2021–2023 (USD MILLION)     146

TABLE 71           CARDIAC TISSUE ENGINEERING MARKET, BY REGION, 2024–2029 (USD MILLION)     146

TABLE 72           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2021–2023 (USD MILLION)          148

TABLE 73           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2024–2029 (USD MILLION)          148

TABLE 74           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          148

TABLE 75           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          149

TABLE 76           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION) 149

TABLE 77           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION) 149

TABLE 78           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)     150

TABLE 79           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)     150

TABLE 80           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          150

TABLE 81           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          151

TABLE 82           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)     151

TABLE 83           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)     151

TABLE 84           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          152

TABLE 85           NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          152

TABLE 86           US: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          153

TABLE 87           US: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          153

TABLE 88           US: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          154

TABLE 89           US: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          154

TABLE 90           US: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)      154

TABLE 91           US: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)      155

TABLE 92           US: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          155

TABLE 93           US: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          155

TABLE 94           US: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          156

TABLE 95           US: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          156

TABLE 96           US: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          156

TABLE 97           US: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          157

TABLE 98           CANADA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             157

TABLE 99           CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          158

TABLE 100         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)        158

TABLE 101         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          158

TABLE 102         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          159

TABLE 103         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          159

TABLE 104         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          159

TABLE 105         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          160

TABLE 106         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          160

TABLE 107         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          160

TABLE 108         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          161

TABLE 109         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          161

TABLE 110         CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          161

TABLE 111         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2021–2023 (USD MILLION)          162

TABLE 112         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2024–2029 (USD MILLION)          163

TABLE 113         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          163

TABLE 114         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          163

TABLE 115         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          164

TABLE 116         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          164

TABLE 117         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          164

TABLE 118         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          165

TABLE 119         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          165

TABLE 120         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          165

TABLE 121         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          166

TABLE 122         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          166

TABLE 123         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          166

TABLE 124         EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          167

TABLE 125         UK: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          168

TABLE 126         UK: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          168

TABLE 127         UK: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          168

TABLE 128         UK: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          169

TABLE 129         UK: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)      169

TABLE 130         UK: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)      169

TABLE 131         UK: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          170

TABLE 132         UK: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          170

TABLE 133         UK: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          170

TABLE 134         UK: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          171

TABLE 135         UK: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          171

TABLE 136         UK: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          171

TABLE 137         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          173

TABLE 138         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          173

TABLE 139         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          173

TABLE 140         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          174

TABLE 141         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          174

TABLE 142         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          174

TABLE 143         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          175

TABLE 144         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          175

TABLE 145         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)        175

TABLE 146         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          176

TABLE 147         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          176

TABLE 148         GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          176

TABLE 149         FRANCE: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             177

TABLE 150         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          178

TABLE 151         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          178

TABLE 152         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          178

TABLE 153         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          179

TABLE 154         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          179

TABLE 155         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          179

TABLE 156         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          180

TABLE 157         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          180

TABLE 158         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          180

TABLE 159         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          181

TABLE 160         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          181

TABLE 161         FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          181

TABLE 162         ITALY: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             182

TABLE 163         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          182

TABLE 164         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          183

TABLE 165         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          183

TABLE 166         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          183

TABLE 167         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          184

TABLE 168         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          184

TABLE 169         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          184

TABLE 170         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          185

TABLE 171         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          185

TABLE 172         ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          185

TABLE 173        ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          186

TABLE 174        ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          186

TABLE 175         SPAIN: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             187

TABLE 176         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          187

TABLE 177         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          188

TABLE 178         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          188

TABLE 179         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)        188

TABLE 180         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          189

TABLE 181         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          189

TABLE 182         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          189

TABLE 183         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          190

TABLE 184         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          190

TABLE 185         SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          190

TABLE 186        SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          191

TABLE 187        SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          191

TABLE 188         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          192

TABLE 189         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          192

TABLE 190         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION) 192

TABLE 191         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION) 193

TABLE 192         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)     193

TABLE 193         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)     193

TABLE 194         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)        194

TABLE 195         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          194

TABLE 196         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)     194

TABLE 197         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)     195

TABLE 198         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          195

TABLE 199         REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          195

TABLE 200         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2021–2023 (USD MILLION)        198

TABLE 201         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2024–2029 (USD MILLION)          198

TABLE 202         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)        199

TABLE 203         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          199

TABLE 204         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)      199

TABLE 205         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)      200

TABLE 206         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          200

TABLE 207         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          200

TABLE 208         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          201

TABLE 209         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          201

TABLE 210         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          201

TABLE 211         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          202

TABLE 212         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          202

TABLE 213         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          202

TABLE 214         JAPAN: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             203

TABLE 215         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          204

TABLE 216         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          204

TABLE 217         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          204

TABLE 218         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          205

TABLE 219         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          205

TABLE 220         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          205

TABLE 221         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          206

TABLE 222         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          206

TABLE 223         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          206

TABLE 224         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          207

TABLE 225         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          207

TABLE 226         JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          207

TABLE 227         CHINA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             208

TABLE 228         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          209

TABLE 229         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          209

TABLE 230         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          209

TABLE 231         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          210

TABLE 232         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          210

TABLE 233         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          210

TABLE 234         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          211

TABLE 235         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          211

TABLE 236         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          211

TABLE 237         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          212

TABLE 238         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          212

TABLE 239         CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          212

TABLE 240         INDIA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             213

TABLE 241         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          214

TABLE 242         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          214

TABLE 243         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          214

TABLE 244         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          215

TABLE 245         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL TYPE,

2021–2023 (USD MILLION)          215

TABLE 246         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL TYPE,

2024–2029 (USD MILLION)          215

TABLE 247         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)        216

TABLE 248         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)        216

TABLE 249         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)        216

TABLE 250         INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          217

TABLE 251        INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          217

TABLE 252        INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          217

TABLE 253         AUSTRALIA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             218

TABLE 254         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          219

TABLE 255         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          219

TABLE 256         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          219

TABLE 257         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          220

TABLE 258         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          220

TABLE 259         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          220

TABLE 260         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          221

TABLE 261         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          221

TABLE 262         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)        221

TABLE 263         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)        222

TABLE 264         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          222

TABLE 265         AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          222

TABLE 266         SOUTH KOREA: KEY MACROINDICATORS FOR CARDIAC

TISSUE ENGINEERING MARKET 223

TABLE 267         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)        224

TABLE 268         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          224

TABLE 269         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)      224

TABLE 270         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)      225

TABLE 271         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          225

TABLE 272         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          225

TABLE 273         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          226

TABLE 274         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          226

TABLE 275         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          226

TABLE 276         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          227

TABLE 277         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          227

TABLE 278         SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          227

TABLE 279         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)        229

TABLE 280         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)        229

TABLE 281         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)           229

TABLE 282         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)           230

TABLE 283         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION) 230

TABLE 284         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION) 230

TABLE 285         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)        231

TABLE 286         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)        231

TABLE 287         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)  231

TABLE 288         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)  232

TABLE 289         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2021–2023 (USD MILLION)         232

TABLE 290         REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2024–2029 (USD MILLION)         232

TABLE 291         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2021–2023 (USD MILLION)          233

TABLE 292         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,

2024–2029 (USD MILLION)          234

TABLE 293         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          234

TABLE 294         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          234

TABLE 295         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)      235

TABLE 296         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)      235

TABLE 297         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          235

TABLE 298         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          236

TABLE 299         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          236

TABLE 300         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          236

TABLE 301         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          237

TABLE 302         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          237

TABLE 303         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          237

TABLE 304         LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          238

TABLE 305         BRAZIL: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             238

TABLE 306         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          239

TABLE 307         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          239

TABLE 308         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          239

TABLE 309         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)          240

TABLE 310         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          240

TABLE 311         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          240

TABLE 312         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          241

TABLE 313         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          241

TABLE 314         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION ,

2021–2023 (USD MILLION)          241

TABLE 315         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          242

TABLE 316         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          242

TABLE 317         BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          242

TABLE 318         MEXICO: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET             243

TABLE 319         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)          244

TABLE 320         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)          244

TABLE 321         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2021–2023 (USD MILLION)          244

TABLE 322         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,

2024–2029 (USD MILLION)        245

TABLE 323         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)          245

TABLE 324         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)          245

TABLE 325         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          246

TABLE 326         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          246

TABLE 327         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2021–2023 (USD MILLION)          246

TABLE 328         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,

2024–2029 (USD MILLION)          247

TABLE 329         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          247

TABLE 330         MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          247

TABLE 331         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)        248

TABLE 332         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)        248

TABLE 333         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)           249

TABLE 334         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)           249

TABLE 335         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION) 249

TABLE 336         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION) 250

TABLE 337         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)        250

TABLE 338         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)        250

TABLE 339         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,

BY APPLICATION, 2021–2023 (USD MILLION)     251

TABLE 340         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,

BY APPLICATION, 2024–2029 (USD MILLION)     251

TABLE 341         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,

BY END USER, 2021–2023 (USD MILLION)            251

TABLE 342         REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,

BY END USER, 2024–2029 (USD MILLION)            252

TABLE 343         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2023 (USD MILLION)         253

TABLE 344         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY, 2024–2029 (USD MILLION)         253

TABLE 345         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)        253

TABLE 346         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)        254

TABLE 347         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)           254

TABLE 348         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)           254

TABLE 349         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION) 255

TABLE 350         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION) 255

TABLE 351         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)        255

TABLE 352         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)        256

TABLE 353         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY APPLICATION, 2021–2023 (USD MILLION)     256

TABLE 354         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY APPLICATION, 2024–2029 (USD MILLION)     256

TABLE 355         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2021–2023 (USD MILLION)         257

TABLE 356         MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2024–2029 (USD MILLION)         257

TABLE 357         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2021–2023 (USD MILLION)        258

TABLE 358         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,

2024–2029 (USD MILLION)        258

TABLE 359         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION) 258

TABLE 360         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION) 259

TABLE 361         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)     259

TABLE 362         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)     259

TABLE 363         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2021–2023 (USD MILLION)          260

TABLE 364         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,

2024–2029 (USD MILLION)          260

TABLE 365         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)     260

TABLE 366         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)     261

TABLE 367         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2021–2023 (USD MILLION)          261

TABLE 368         GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,

2024–2029 (USD MILLION)          261

TABLE 369         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY MATERIAL, 2021–2023 (USD MILLION)          262

TABLE 370         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY MATERIAL, 2024–2029 (USD MILLION)           262

TABLE 371         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY SCAFFOLD TYPE, 2021–2023 (USD MILLION) 263

TABLE 372         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY SCAFFOLD TYPE, 2024–2029 (USD MILLION) 263

TABLE 373         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)     263

TABLE 374         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)     264

TABLE 375         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY PRODUCT, 2021–2023 (USD MILLION)          264

TABLE 376         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY PRODUCT, 2024–2029 (USD MILLION)            264

TABLE 377         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY APPLICATION, 2021–2023 (USD MILLION)     265

TABLE 378         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY APPLICATION, 2024–2029 (USD MILLION)   265

TABLE 379         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY END USER, 2021–2023 (USD MILLION)            265

TABLE 380         REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,

BY END USER, 2024–2029 (USD MILLION)            266

TABLE 381         OVERVIEW OF STRATEGIES DEPLOYED BY CARDIAC TISSUE ENGINEERING

MARKET PLAYERS         267

TABLE 382         CARDIAC TISSUE ENGINEERING MARKET: DEGREE OF COMPETITION 270

TABLE 383         CARDIAC TISSUE ENGINEERING MARKET: REGION FOOTPRINT      276

TABLE 384         CARDIAC TISSUE ENGINEERING MARKET: APPLICATION FOOTPRINT      277

TABLE 385         CARDIAC TISSUE ENGINEERING MARKET: PRODUCT FOOTPRINT      278

TABLE 386         CARDIAC TISSUE ENGINEERING MARKET: MATERIAL FOOTPRINT      279

TABLE 387         CARDIAC TISSUE ENGINEERING: END USER FOOTPRINT              280

TABLE 388         CARDIAC TISSUE ENGINEERING MARKET: KEY STARTUPS/SMES           282

TABLE 389         CARDIAC TISSUE ENGINEERING MARKET: COMPETITIVE BENCHMARKING

OF KEY EMERGING PLAYERS/STARTUPS            282

TABLE 390         CARDIAC TISSUE ENGINEERING MARKET: PRODUCT LAUNCHES,

JANUARY 2020–JUNE 2023           283

TABLE 391         CARDIAC TISSUE ENGINEERING MARKET: DEALS, JANUARY 2020–JUNE 2024 284

TABLE 392         TERUMO CORPORATION: COMPANY OVERVIEW           287

TABLE 393         TERUMO CORPORATION: PRODUCTS OFFERED            288

TABLE 394         ARTIVION, INC.: COMPANY OVERVIEW 290

TABLE 395         ARTIVION, INC.: PRODUCTS OFFERED 291

TABLE 396         ARTIVION, INC.: DEALS, JANUARY 2020–JUNE 2024          292

TABLE 397         BAXTER INTERNATIONAL, INC: COMPANY OVERVIEW 294

TABLE 398         BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED 295

TABLE 399         BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2020–JUNE 2024      296

TABLE 400         TEIJIN LIMITED: COMPANY OVERVIEW 297

TABLE 401         TEIJIN LIMITED: PRODUCTS OFFERED 298

TABLE 402         MEDTRONIC PLC: COMPANY OVERVIEW           300

TABLE 403         MEDTRONIC PLC: PRODUCTS OFFERED            301

TABLE 404         MEDTRONIC PLC: DEALS, JANUARY 2020–JUNE 2024      302

TABLE 405         BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW              304

TABLE 406         BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED              305

TABLE 407         ABBOTT LABORATORIES: COMPANY OVERVIEW            306

TABLE 408         ABBOTT LABORATORIES: PRODUCTS OFFERED            307

TABLE 409         ABBOTT LABORATORIES: DEALS, JANUARY 2020–JUNE 2024              308

TABLE 410         MERCK KGAA: COMPANY OVERVIEW    309

TABLE 411         MERCK KGAA: PRODUCTS OFFERED     310

TABLE 412         FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW              311

TABLE 413         FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED              312

TABLE 414         BICO- THE BIO CONVERGENCE COMPANY: COMPANY OVERVIEW        313

TABLE 415         BICO – THE BIO CONVERGENCE COMPANY: PRODUCTS OFFERED          314

TABLE 416         ELUTIA: COMPANY OVERVIEW 315

TABLE 417         ELUTIA: PRODUCTS OFFERED  316

TABLE 418         W.L. GORE AND ASSOCIATES, INC.: COMPANY OVERVIEW              317

TABLE 419         W.L. GORE AND ASSOCIATES, INC.: PRODUCTS OFFERED              317

TABLE 420         MERIL LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW 318

TABLE 421         MERIL LIFESCIENCES PVT. LTD.: PRODUCTS OFFERED 318

TABLE 422         VASCUDYNE, INC.: COMPANY OVERVIEW          319

TABLE 423         VASCUDYNE, INC.: PRODUCTS OFFERED           319

TABLE 424         REPROCELL, INC.: COMPANY OVERVIEW           321

TABLE 425         REPROCELL, INC.: PRODUCTS OFFERED            321

TABLE 426         REPROCELL: DEALS, JANUARY 2020–JUNE 2024  322

LIST OF FIGURES

FIGURE 1           CARDIAC TISSUE ENGINEERING MARKET: RESEARCH DESIGN              38

FIGURE 2           PRIMARY SOURCES       41

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION    43

FIGURE 4           MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 44

FIGURE 5           TOP-DOWN APPROACH             44

FIGURE 6          CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    46

FIGURE 7           CAGR PROJECTIONS     46

FIGURE 8           DATA TRIANGULATION METHODOLOGY         48

FIGURE 9           STEM CELLS TO BE LARGEST MATERIAL SEGMENT DURING FORECAST PERIOD       51

FIGURE 10         BIOLOGICAL SCAFFOLDS SEGMENT TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD 52

FIGURE 11         COLLAGEN-BASED SCAFFOLDS TO LEAD DURING FORECAST PERIOD              52

FIGURE 12         VASCULAR GRAFTS HELD LARGEST SHARE IN 2023        53

FIGURE 13         MYOCARDIAL INFARCTION TO BE LEADING SEGMENT DURING FORECAST PERIOD     54

FIGURE 14         HOSPITALS & CLINICS TO DOMINATE MARKET DURING FORECAST PERIOD       54

FIGURE 15         ASIA PACIFIC TO BE FASTEST-GROWING REGIONAL MARKET FOR

CARDIAC TISSUE ENGINEERING            55

FIGURE 16         RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET GROWTH          57

FIGURE 17         MYOCARDIAL INFARCTION DOMINATED EUROPEAN CARDIAC TISSUE ENGINEERING MARKET IN 2023           58

FIGURE 18         INDIAN MARKET TO GROW FASTEST DURING FORECAST PERIOD              59

FIGURE 19         ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD       60

FIGURE 20         DEVELOPING MARKETS TO REGISTER FASTER GROWTH DURING

FORECAST PERIOD       60

FIGURE 21         CARDIAC TISSUE ENGINEERING MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES    61

FIGURE 22         DEVELOPMENT OF BIOCOMPATIBLE AND BIODEGRADABLE MATERIALS:

LEADING TRENDS         68

FIGURE 23         CARDIAC TISSUE ENGINEERING MARKET: VALUE CHAIN ANALYSIS          75

FIGURE 24         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARDIAC TISSUE ENGINEERING PRODUCTS     77

FIGURE 25         KEY BUYING CRITERIA FOR CARDIAC TISSUE ENGINEERING PRODUCTS       78

FIGURE 26         CARDIAC TISSUE ENGINEERING: NUMBER OF PATENTS PUBLISHED (JANUARY 2014–MAY 2024) 82

FIGURE 27         CARDIAC TISSUE ENGINEERING: TOP PATENT APPLICANTS & OWNERS (JANUARY 2014–MAY 2024)      83

FIGURE 28         TOP APPLICANT COUNTRIES/REGIONS FOR CARDIAC TISSUE ENGINEERING (JANUARY 2014–MAY 2024)          84

FIGURE 29         CARDIAC TISSUE ENGINEERING MARKET ECOSYSTEM 90

FIGURE 30         CARDIAC TISSUE ENGINEERING MARKET: SUPPLY CHAIN ANALYSIS          95

FIGURE 31         CARDIAC TISSUE ENGINEERING MARKET: INVESTMENT AND FUNDING SCENARIO (2018–2023)           96

FIGURE 32         TISSUE ENGINEERING MARKET OVERVIEW       97

FIGURE 33         CARDIAC TISSUE ENGINEERING MARKET: REGIONAL SNAPSHOT        145

FIGURE 34         NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET SNAPSHOT        147

FIGURE 35         ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET SNAPSHOT        197

FIGURE 36         REVENUE ANALYSIS OF KEY COMPANIES (2019–2023)    268

FIGURE 37         CARDIAC TISSUE ENGINEERING: MARKET SHARE ANALYSIS (2023)   269

FIGURE 38         EV/EBITDA OF KEY VENDORS   272

FIGURE 39         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS             272

FIGURE 40         CARDIAC TISSUE ENGINEERING MARKET: COMPANY EVALUATION

MATRIX (KEY PLAYERS), 2023    274

FIGURE 41         CARDIAC TISSUE ENGINEERING MARKET: COMPANY FOOTPRINT      275

FIGURE 42         CARDIAC TISSUE ENGINEERING MARKET: COMPANY EVALUATION MATRIX, STARTUPS/SMES (2023) 281

FIGURE 43         CARDIAC TISSUE ENGINEERING MARKET: BRAND/PRODUCT

COMPARATIVE ANALYSIS        286

FIGURE 44         TERUMO CORPORATION: COMPANY SNAPSHOT           288

FIGURE 45         ARTIVION, INC.: COMPANY SNAPSHOT 291

FIGURE 46         BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT 295

FIGURE 47         TEIJIN LIMITED: COMPANY SNAPSHOT 298

FIGURE 48         MEDTRONIC PLC: COMPANY SNAPSHOT           301

FIGURE 49         BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT              305

FIGURE 50         ABBOTT LABORATORIES: COMPANY SNAPSHOT           307

FIGURE 51         MERCK KGAA: COMPANY SNAPSHOT    310

FIGURE 52         FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT              312

FIGURE 53         BICO – THE BIO CONVERGENCE COMPANY: COMPANY SNAPSHOT        314

FIGURE 54         ELUTIA: COMPANY SNAPSHOT 316

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧